Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Up 6.5% – Should You Buy?

Fulcrum Therapeutics, Inc. (NASDAQ:FULC)’s share price was up 6.5% during trading on Thursday . The company traded as high as $11.42 and last traded at $11.6540. Approximately 66,428 shares changed hands during trading, a decline of 90% from the average daily volume of 662,627 shares. The stock had previously closed at $10.94.

Wall Street Analysts Forecast Growth

FULC has been the subject of several research reports. Royal Bank Of Canada increased their price target on shares of Fulcrum Therapeutics from $7.00 to $10.00 and gave the company a “sector perform” rating in a research report on Monday, December 8th. Stifel Nicolaus set a $25.00 price target on shares of Fulcrum Therapeutics in a report on Monday, December 8th. Piper Sandler reissued an “overweight” rating and set a $23.00 price objective (up from $16.00) on shares of Fulcrum Therapeutics in a report on Monday, December 8th. Wall Street Zen downgraded Fulcrum Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, January 17th. Finally, Cantor Fitzgerald boosted their target price on Fulcrum Therapeutics from $15.00 to $24.00 and gave the company an “overweight” rating in a research note on Monday, December 8th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $19.11.

Fulcrum Therapeutics Stock Performance

The business has a 50 day moving average of $10.91 and a 200-day moving average of $9.40. The company has a market capitalization of $595.32 million, a P/E ratio of -9.32 and a beta of 3.19.

Insiders Place Their Bets

In other news, Director Robert J. Gould sold 15,000 shares of Fulcrum Therapeutics stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $11.87, for a total transaction of $178,050.00. Following the completion of the sale, the director owned 469,864 shares in the company, valued at approximately $5,577,285.68. This trade represents a 3.09% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Ra Capital Management, L.P. sold 4,175,139 shares of the firm’s stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $13.98, for a total transaction of $58,368,443.22. Following the completion of the sale, the insider directly owned 6,053,960 shares in the company, valued at $84,634,360.80. This represents a 40.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 7.00% of the company’s stock.

Institutional Trading of Fulcrum Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in FULC. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Fulcrum Therapeutics during the fourth quarter valued at about $30,000. Meeder Asset Management Inc. bought a new position in Fulcrum Therapeutics during the fourth quarter valued at approximately $39,000. Quarry LP purchased a new position in Fulcrum Therapeutics in the 3rd quarter worth $35,000. Persistent Asset Partners Ltd purchased a new stake in Fulcrum Therapeutics during the fourth quarter valued at about $75,000. Finally, Farther Finance Advisors LLC grew its stake in shares of Fulcrum Therapeutics by 108.3% during the third quarter. Farther Finance Advisors LLC now owns 7,112 shares of the company’s stock valued at $65,000 after buying an additional 3,697 shares during the last quarter. Hedge funds and other institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.